Pfizer, like some other big drug makers, is facing tepid growth amid generic competition and the lack of clear blockbusters in its drug pipeline. 和其它大型制藥企業(yè)一樣，輝瑞也面臨著(zhù)因普通藥物的競爭而導致的業(yè)務(wù)增長(cháng)緩慢，同時(shí)它研制的藥物中尚缺乏能帶來(lái)巨大效益的轟動(dòng)性藥物。
The research progress on applications of MIP in chiral drug separation and clinical drug analysis in the recent years was expounded. 綜述了近年來(lái)分子印跡聚合物在手性藥物分離和臨床藥物分析應用方面的研究進(jìn)展。
